Alector, Inc. (ALEC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.46-1.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Alector aims to grow revenue to about $15.5 million in 2025. The company plans to keep enough cash to operate through 2027. Recent earnings beats show some progress. Cost cuts and leadership changes may improve results.
Alector is still losing money and faces high risks. Revenue and earnings may stay weak. The recent stock selloff shows investor doubts. The company may need more cash soon.
The price is about 17% below our fair value near $2.3. Analysts expect about 16% revenue growth. Our view sees risk in the turnaround and cash runway.
Breaks if: Cash runway falls short of 2027
Ensure sufficient cash, cash equivalents, and investments to fund operations at least through 2027.
Stated in 2026-Q1 and 2026-Q2. Cash and investments declined from $206.5M at 2026-Q1 to $172.8M at 2026-Q2, reflecting cash burn. Management maintains that this cash position is sufficient to fund operations through 2027. The trajectory shows ongoing cash usage but management affirms runway sufficiency.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is intact, driven by recent earnings performance, but the company is still navigating challenges in its therapeutic pipeline and cash management.
The market appears to price in a significant expectations gap, indicating that investors may not fully believe in the company's ability to execute its plans. Valuation is at a premium compared to peers, suggesting that some optimism is already reflected in the stock.
Fundamentals are likely to remain mixed in the near term. Management's focus on advancing the therapeutic pipeline and controlling expenses is evident, but cash burn remains a concern as revenue fluctuates.
The thesis hinges on several key factors. If management cuts guidance or if economic indicators worsen, the outlook could shift unfavorably. Conversely, continued success from sector leaders could bolster ALEC's performance.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Cash, cash equivalents and investments provide runway at least through 2027.”
“Management anticipates that this will be sufficient to fund Alector’s operations at least through 2027.”
Breaks if: EPS loss worsens beyond -$0.88 in 2027
Breaks if: Revenue falls below ~$13 million in 2025
Over the next 1 to 3 years, ALEC's performance will depend on its ability to manage risks while advancing its pipeline. Not investment advice.